Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 215

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Mortality with Paclitaxel-Coated Devices in Peripheral Artery Disease

Nordanstig, Joakim, James, Stefan, Andersson, Manne, Andersson, Mattias, Danielsson, Peter, Gillgren, Peter, Delle, Martin, Engström, Jan, Fransson, Torbjörn, Hamoud, Maher, Hilbertson, Anna, Johansson, Patrik, Karlsson, Lars, Kragsterman, Björn, Lindgren, Hans, Ludwigs, Karin, Mellander, Stefan, Nyman, Niklas, Renlund, Henrik, Sigvant, Birgitta, Skoog, Per, Starck, Joachim, Tegler, Gustaf, Toivola, Asko, Truedson, Maria, Wahlgren, Carl-Magnus, Wallinder, Jonas, Öjersjö, Andreas, Falkenberg, Mårten · 2020 · New England Journal of Medicine

Abstract

BACKGROUND: The results of a recent meta-analysis aroused concern about an increased risk of death associated with the use of paclitaxel-coated angioplasty balloons and stents in lower-limb endovascular interventions for symptomatic peripheral artery disease. METHODS: We conducted an unplanned interim analysis of data from a multicenter, randomized, open-label, registry-based clinical trial. At the time of the analysis, 2289 patients had been randomly assigned to treatment with drug-coated devices (the drug-coated-device group, 1149 patients) or treatment with uncoated devices (the uncoated-device group, 1140 patients). Randomization was stratified according to disease severity on the basis of whether patients had chronic limb-threatening ischemia (1480 patients) or intermittent claudication (809 patients). The single end point for this interim analysis was all-cause mortality. RESULTS: No patients were lost to follow-up. Paclitaxel was used as the coating agent for all the drug-coated devices. During a mean follow-up of 2.49 years, 574 patients died, including 293 patients (25.5%) in the drug-coated-device group and 281 patients (24.6%) in the uncoated-device group (hazard ratio, 1.06; 95% confidence interval, 0.92 to 1.22). At 1 year, all-cause mortality was 10.2% (117 patients) in the drug-coated-device group and 9.9% (113 patients) in the uncoated-device group. During the entire follow-up period, there was no significant difference in the incidence of death between the treatment groups among patients with chronic limb-threatening ischemia (33.4% [249 patients] in the drug-coated-device group and 33.1% [243 patients] in the uncoated-device group) or among those with intermittent claudication (10.9% [44 patients] and 9.4% [38 patients], respectively). CONCLUSIONS: In this randomized trial in which patients with peripheral artery disease received treatment with paclitaxel-coated or uncoated endovascular devices, the results of an unplanned interim analysis of all-cause mortality did not show a difference between the groups in the incidence of death during 1 to 4 years of follow-up. (Funded by the Swedish Research Council and others; ClinicalTrials.gov number, NCT02051088.).

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1056/nejmoa2005206

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 215

Metadata

Authors
Nordanstig, J., James, S., Andersson, M., Andersson, M., Danielsson, P., Gillgren, P., Delle, M., Engström, J., Fransson, T., Hamoud, M., Hilbertson, A., Johansson, P., Karlsson, L., Kragsterman, B., Lindgren, H., Ludwigs, K., Mellander, S., Nyman, N., Renlund, H., Sigvant, B., Skoog, P., Starck, J., Tegler, G., Toivola, A., Truedson, M., Wahlgren, C.-M., Wallinder, J., Öjersjö, A., & Falkenberg, M.
Venue
New England Journal of Medicine
Published
2020-12-24
Volume
383
Issue
26
Pages
2538-2546
ISSN
  • 0028-4793 (ISSN-L)
  • 1533-4406
OpenAlex
W3111317163
Cited by
215
References
1
FWCI
29.78
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.